TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BeOne Medicines ( (ONC) ) has shared an announcement.
On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial institutions, securing senior secured financing through various loan facilities totaling approximately $1 billion. The agreement includes a U.S. dollar-denominated revolving loan and term loan facilities, as well as a Renminbi-denominated term loan facility. The funds are intended for general corporate purposes, refinancing existing debt, and other specified uses. The agreement also outlines security interests, interest rates, repayment schedules, and conditions for prepayment, along with customary covenants and events of default.
The most recent analyst rating on (ONC) stock is a Buy with a $420.00 price target. To see the full list of analyst forecasts on BeOne Medicines stock, see the ONC Stock Forecast page.
Spark’s Take on ONC Stock
According to Spark, TipRanks’ AI Analyst, ONC is a Neutral.
The strong earnings call and positive technical indicators are the most significant factors driving the score. Financial performance shows potential but is hindered by profitability challenges. Valuation concerns due to a high P/E ratio also weigh on the overall score.
To see Spark’s full report on ONC stock, click here.
More about BeOne Medicines
Average Trading Volume: 280,096
Technical Sentiment Signal: Buy
Current Market Cap: $41.02B
For a thorough assessment of ONC stock, go to TipRanks’ Stock Analysis page.